carmustine has been researched along with amifostine anhydrous in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Glover, DJ | 1 |
| Cathcart, KN; Crawford, JM; Flatow, J; Holden, SA; Lin, Y; Luchette, CA; Teicher, BA | 1 |
| Abushamaa, AM; Folz, RJ; Sporn, TA | 1 |
| Blume, KG; Dansey, R; Jones, RB; Klein, J; Martinez, C; Matthes, S; Murphy, J; Nieto, Y; Stockerl-Goldstein, KE | 1 |
| Abboud, CN; Bernstein, SH; Chapman, M; Friedberg, JW; Ifthikharuddin, JJ; Johnson, V; Lancet, JE; Liesveld, JL; Phillips, GL; Spreng, E; Vesole, DH | 1 |
| Bakshi, A; Bhagwat, R; Biswas, G; Khadwal, A; Narayanan, P; Parikh, P; Sastry, P | 1 |
| Abboud, CN; Becker, MW; Bernstein, SH; Constine, LS; Friedberg, JW; Ifthikharuddin, JJ; Liesveld, JL; Loughner, JE; Milner, LA; Phillips, GL; Vesole, DH | 1 |
| Calandrelli, M; Capelli, D; Chiarucci, M; Gini, G; Inglese, E; Leoni, P; Mancini, G; Mancini, S; Montanari, M; Offidani, M; Olivieri, A; Poloni, A; Raggetti, G; Scortechini, I | 1 |
4 trial(s) available for carmustine and amifostine anhydrous
| Article | Year |
|---|---|
A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects.
Topics: Adult; Amifostine; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Cyclophosphamide; Double-Blind Method; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Placebos; Radiation-Protective Agents; Respiratory Distress Syndrome; Treatment Outcome | 2004 |
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Cytoprotection; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Radiation-Protective Agents; Transplantation, Autologous | 2004 |
Trial of amifostine in autologous stem cell transplant.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Female; Graft Survival; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Radiation-Protective Agents; Stem Cell Transplantation; Transplantation, Homologous | 2006 |
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carmustine; Combined Modality Therapy; Cytarabine; Cytoprotection; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Mucositis; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2011 |
7 other study(ies) available for carmustine and amifostine anhydrous
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
New approaches to the chemotherapy of melanoma.
Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Daunorubicin; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Paclitaxel; Procarbazine; Tamoxifen; Taurine; Thiotepa; Vincristine; Vindesine | 1991 |
Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide.
Topics: Amifostine; Animals; Carmustine; Cell Line; Cyclophosphamide; Drug Interactions; Fibrosarcoma; Glutathione; Liver; Mice; Mice, Inbred C3H; Mitomycin; Mitomycins; Monocrotaline; Pyrrolizidine Alkaloids | 1988 |
Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen.
Topics: Amifostine; Animals; Antineoplastic Agents, Alkylating; Antioxidants; Blood Cell Count; Body Weight; Bronchoalveolar Lavage Fluid; Carmustine; Cell Count; Extracellular Space; Female; Glutathione; Glutathione Disulfide; Glutathione Reductase; In Vitro Techniques; Lipid Peroxides; Lung; Mice; Mice, Inbred Strains; Oxidative Stress; Pneumonia | 2002 |
Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Outpatients; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |